Provider Networks & IPAs
Expert articles and analysis related to provider networks & ipas.
AI Summary — Last 30 Days
CMS is pushing physician payment more explicitly toward accountable care, with proposed Medicare reforms that would phase out MIPS, strengthen primary care payment, and expand ACO participation—moves that could make IPA/network infrastructure more valuable as the organizing layer for independent physicians entering downside-risk arrangements. At the same time, CMS-reported 2024 ACO REACH savings of nearly $1B are giving policymakers and industry groups more evidence to defend advanced ACO models, even as providers face operational strain from AI governance gaps, drug-cost pressures, and Medicaid experiments such as Indiana’s GLP-1 coverage under the BALANCE model. For health systems, IPAs, and payers, the strategic signal is clear: build tighter physician alignment, data operations, and care management capacity now, because Medicare policy is increasingly rewarding organizations that can aggregate providers and manage total cost of care at scale ([CMS physician pay reforms](https://news.google.com/rss/articles/CBMiywFBVV95cUxNT2dHa2MyVEVua1lDYWducm1nTVBZSl8weTJ3QU16czJ1TEVqMEMxT2ZJQU4xSjdRLXo2TEVDZzhJb3F6a2pHbzlMOXUzWFlFSGRSYjMyb0ZFcWZpSWlEZmpNTzVpVndtclh2T2Jhb2EyWllh
Related Articles
Lower Costs, More Paperwork: New Barriers to Prescription Drugs
Prescription drug costs and patient access have long been major concerns. With the Inflation Reduction Act, policymakers cut patients’ drug costs by limiting out-of-pocket expenses and mandating cover...
CMS proposes 340B cuts
A proposed rule would cut the rates by which Medicare pays hospitals for 340B drugs by more than a third, reviving a similar policy introduced by the first Trump administration. CMS said on Thursday...
Part B Negotiated Drug Prices: How MA Plans Should Prepare
How PBM Reform Is Reshaping the Operational Environment for Pharma Manufacturers
How PBM Reform Is Reshaping the Operational Environment for Pharma Manufacturers  Pharmaceutical Commerce
UK price watchdog recommends against Amgen's Lumakras in lung cancer
The UK’s drug pricing watchdog said government reimbursement of Amgen’s lung cancer drug Lumakras should be cut off for new patients. In draft guidance released on Thursday, the National Institute f...
Tampa General sues Eli Lilly for allegedly pulling 340B discounts
Tampa General sues Eli Lilly for allegedly pulling 340B discounts  Healthcare Finance News
Tampa General Hospital sues Eli Lilly over pulled 340B discounts
Tampa General Hospital sues Eli Lilly over pulled 340B discounts  Fierce Healthcare
What are copay accumulators?
KFF reports on the increased use of copay accumulators: Oscar Health is one of many commercial health insurers that use what are often called copay accumulator programs to keep funds that are meant to...
Tampa General sues Eli Lilly over pulled 340B discounts
Tampa General sues Eli Lilly over pulled 340B discounts  Becker's Hospital Review
Prime Therapeutics, Express Scripts face price-fixing allegations
Prime Therapeutics, Express Scripts face price-fixing allegations  Modern Healthcare